It was also observed that ribociclib, a cyclin-dependent kinase inhibitor that slows cancer cell growth by inhibiting CDK4/6 proteins, significantly decreased viability in the healthy cell line in addition to its effect in the carcinoma cell line. This evidence concerns the gene CDK4 and carcinoma.